David Domzalski - Jan 21, 2025 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Mutya Harsch, Attorney-in-Fact
Stock symbol
VYNE
Transactions as of
Jan 21, 2025
Transactions value $
$0
Form type
4
Date filed
1/23/2025, 04:15 PM
Previous filing
Jan 2, 2025
Next filing
Apr 2, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VYNE Stock Option (right to buy) Award $0 +730K $0.00 730K Jan 21, 2025 Common Stock 730K $2.77 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2026 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.